Organisation paid for research Program year 2024 Source: CMS Open Payments

Tekton Research - Beaumont - PPDS

Neither a doctor nor a teaching hospital

Research payments

$26,074,554

5,843 payments

Through program year 2024, Tekton Research - Beaumont - PPDS is reported as receiving $26,074,554 in research payments, across 5,843 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2024	Research	$16,511,621	1,263
2023	Research	$9,562,933	4,580

Breakdown

Who paid Research payments · program years 2023–2024

Moderna TX, Inc. $26,074,554 5,843 payments

Studies the money was for Research payments · program years 2023–2024

A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $6,805,424 2,527 payments
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. $4,084,785 168 payments
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $4,039,780 275 payments
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age $3,340,960 64 payments
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Mrna-1403, A Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults 18 Years of Age $1,354,088 69 payments
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age $1,251,279 299 payments
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $904,299 1,091 payments
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $803,803 209 payments
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, 2-Part, Dose-Ranging Study of an EBV Candidate Vaccine,mRNA-1195, in Healthy Adults 18 to 55 Years of Age $734,869 535 payments
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults $569,235 69 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.